Ingrid A. Binswanger, MD, MPH, MS

Biography

Adjunct Professor

Health Systems Science

Dr. Ingrid A. Binswanger is a Senior Clinician Investigator at the Institute for Health Research and a practicing physician in Chemical Dependency Treatment Services with Kaiser Permanente in the state of Colorado. At KPSOM, Dr. Binswanger enjoys mentoring students on their scholarly projects. Her peer-reviewed research focuses on how to reduce the medical complications of substance use, such as overdose. She also conducts research to reduce the morbidity and mortality of people who have been involved with the criminal legal system. Dr. Binswanger is also a Professor in the Division of General Internal Medicine, where she is the Director for Substance Use Research Development. She also serves as a Principal Investigator for the National Drug Abuse Clinical Trials Network.

Education and Training

Degrees: BA, with distinction, Swarthmore College
MS, School of Public Health, University of California, Berkeley
MD, University of California, Berkeley-University of California, San Francisco Joint Medical Program
MPH, University of Washington, Seattle

Postdoctoral Training: Residency, Primary Care General Internal Medicine, University of California, San Francisco
Fellowship, Robert Wood Johnson Clinical Scholars Program, University of Washington

Professional Positions

Clinical Instructor in Medicine, Division of General Internal Medicine, Department of Medicine: University of Washington; 2003-2004

Attending Physician, Division of General Internal Medicine: Madison Clinic at Harborview; 2003-2004

Assistant Professor of Medicine, Division of General Internal Medicine, Department of Medicine: University of Colorado, Denver/Aurora; 2006-2012

Attending Physician, General Internal Medicine: Bernard F. Gipson Eastside Family Health Center-Denver Health Medical Center; 2006-2014

Attending Physician: Potomac Street Center, Addiction Research and Treatment Services, University of Colorado School of Medicine; 2008-2014

Co-Director, Primary Care Research Fellowship Program: University of Colorado School of Medicine; 2009-2012; 2017-2018

Primary Care Residency Research Director: Primary Care Internal Medicine Residency Program, University of Colorado School of Medicine; 2010-2014

Director, Primary Care Research Fellowship Program: University of Colorado School of Medicine; 2012-2017

Associate Professor of Medicine, Division of General Internal Medicine, Department of Medicine: University of Colorado School of Medicine; 2012-present

Director, Patient Centered Outcomes Research (PCOR) Training Program: University of Colorado School of Medicine-Denver Health Medical Center; 2013-2018

Senior Clinician Investigator, Institute for Health Research: Kaiser Permanente; 2015-present

Physician: Colorado Permanente Medical Group, Chemical Dependency Treatment Services; 2015-present

Adjunct Professor, Health Systems Science: Kaiser Permanente Bernard J. Tyson School of Medicine; 2020-present

Professor of Medicine and Director of Substance Use Research Development, Division of General Internal Medicine, Department of Medicine: University of Colorado School of Medicine; 2024-present

Honors and Awards

Mack Lipkin Senior Associate Award for Scientific Presentation: Society for General Internal Medicine; 2006

Clinical Faculty Scholars Program: Colorado Health Outcomes Program, University of Colorado, Denver; 2007-2009

New Investigator Educator Award: Association for Medical Education and Research in Substance Abuse (AMERSA); 2011

Professional Leadership Award/Women in Medicine and Science: University of Colorado, Denver; 2011

Fellow: American College of Physicians; 2011

Clinician Investigator Award: Society for General Internal Medicine, Mountain West Region; 2011

Leadership for Innovative Team Science Program: Colorado Clinical and Translational Institute; 2013-2014

Most Downloaded Paper of 2016 Award: Substance Abuse Journal; 2016

Multisite Collaborator Award: Health Care Systems Research Network; 2023

Exceptional Women in Medicine: Castle Connolly; 2023-2026

5280 Magazine Top Doctor: Castle Connolly; 2023-2025

Scholarly Activities

: View Dr. Ingrid Binswanger's Researcher Profile

Selected peer-reviewed research manuscripts

Binswanger IA. Opioid Use Disorder and Incarceration: Hope for Ensuring the Continuity of Treatment. New England Journal of Medicine. 2019; Mar 28;380(13):1193-1195.
Binswanger IA, Nguyen AP, Morenoff JD, Xu S, Harding DJ. The association of criminal justice supervision setting with overdose mortality: a longitudinal cohort study. Addiction. 2020;115(12):2329-2338.
Binswanger IA, Rinehart D, Mueller SR, Narwaney KJ, Stowell M, Wagner N, Xu S, Hanratty R, Blum J, McVaney K, Glanz JM. Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial. Journal of General Internal Medicine. 2022 Aug;37(11):2624-2633. (PMC9411391)
Binswanger IA, Shetterly SM, Xu S, Narwaney KJ, McClure DL, Rinehart DJ, Nguyen AP, Glanz JM. Opioid Dose Trajectories and Associations With Mortality, Opioid Use Disorder, Continued Opioid Therapy, and Health Plan Disenrollment. JAMA Netw Open. 2022 Oct 3;5(10):e2234671. doi: 10.1001/jamanetworkopen.2022.34671. (PMC9535531)
Glanz JM, Binswanger IA (co-first author), Clarke CL, Nguyen AP, Ford MA, Ray GT, Xu S, Hechter RC, Yarborough BJH, Roblin DW, Ahmedani B, Boscarino JA, Andrade SE, Rosa CL, Campbell CI. The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatment. Addiction. 2023;Jan;118(1):97-107. doi:10.1111/add.15998. (PMC9722535).
Christine PJ, Goldman AL, Morgan JR, Yan S, Chatterjee A, Bettano AL, Binswanger IA, LaRochelle MR. Insurance Instability for Patients With Opioid Use Disorder in the Year After Diagnosis. JAMA Health Forum. 2024 Jul 5;5(7):e242014.
Jason M Glanz, Shane R Mueller, Komal J Narwaney, Nicole M Wagner, Stanley Xu, Courtney R Kraus, Kris Wain, Sheila Botts, Ingrid A Binswanger - Effectiveness of direct patient outreach with a narrative naloxone and overdose prevention video to patients prescribed long-term opioid therapy in the USA: the Naloxone Navigator randomised clinical trial. BMJ Public Health. 2024;2:e000725.
Pytell JD, Pales D, Simon C, Beaudoin J, Osman AMY, Svoboda E, Christine, PJ, Matlock D, Schwartz R, Binswanger IA. Systematic review of patient-reported outcome measures for opioid use disorder recovery. Addiction. 2026 Mar;121(3):488-498. https://doi.org/10.1111/add.70212
Binswanger IA, Yu O, Wartko PD, Addis M, Bobb JF, Lee AK, Yarborough BJ, Arnsten J, Glass JE, Northrup TF, Murphy M, Braciszewski JM, Horigian VE, Shoup JA, Potter A, Bradley KA. Variability in medication treatment of opioid use disorder in primary care: Comparison of PROUD trial intervention clinics and other exemplar clinics. J Subst Use Addict Treat. 2026 Jan 16;:209896. doi: 10.1016/j.josat.2026.209896.
Nguyen AP, Binswanger IA, Narwaney KJ, Goodrich G, Christine PJ, Campbell CI, Xu S, Loree AM, Glanz JM. Health Plan Disenrollment and Mortality After Initiation of Medications for Opioid Use Disorder. JAMA Psychiatry. 2026 May 1;83(5):491-498.